Evidence map›Paper›PMID 32803845›Full record

ArticleBJOG : an international journal of obstetrics and gynaecology2021

Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

F Gaba, O Blyuss, D Chandrasekaran, M Osman, S Goyal, C Gan, L Izatt, V Tripathi, I Esteban, L McNicol and 6 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BJOG : an international journal of obstetrics and gynaecology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06497270 (A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06497270 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2024 to 2027Enrolled3ConditionsBRCA Mutation, Estrogen Deficiency, Surgical Menopause, Menopause Related ConditionsArmsTheca and Granulosa Cell Isolation
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Surgical decision making in premenopausalJournal of medical genetics · 2022
    Observational
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 2 countries.

F GabaWolfson Institute of Preventive Medicine, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London, UK.ORCID https://orcid.org/0000-0003-4081-6883
O BlyussSchool of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, UK.
D ChandrasekaranWolfson Institute of Preventive Medicine, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London, UK.
M OsmanWolfson Institute of Preventive Medicine, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London, UK.
S GoyalWolfson Institute of Preventive Medicine, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London, UK.
C GanDepartment of Gynaecological Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
L IzattDepartment of Clinical Genetics, Guy's Hospital, London, UK.
V TripathiDepartment of Clinical Genetics, Guy's Hospital, London, UK.
I EstebanNinewells Hospital, NHS Tayside, Dundee, UK.
L McNicolNinewells Hospital, NHS Tayside, Dundee, UK.
K RagupathyNinewells Hospital, NHS Tayside, Dundee, UK.
R CrawfordDepartment of Gynaecological Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
D G EvansManchester Centre for Genomic Medicine, MAHSC, Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK.
R LegoodDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
U MenonMRC Clinical Trials Unit, University College London, London, UK.
R ManchandaWolfson Institute of Preventive Medicine, Cancer Research UK, Barts Centre, Queen Mary University of London, Charterhouse Square, London, UK.ORCID https://orcid.org/0000-0003-3381-5057
NHS Tayside · GBSt Bartholomew's Hospital · GBGuy's Hospital · GBQueen Mary University of London · GBCambridge University Hospitals NHS Foundation Trust · GBLondon School of Hygiene & Tropical Medicine · GBManchester Academic Health Science Centre · GBMRC Clinical Trials Unit at UCL · GBNottingham University Hospitals NHS Trust · GBUniversity of Hertfordshire · GB

Funding

Department of Health IS-BRC-1215-20007Medical Research Council MC_UU_12023/28
6 · The paper itself

Abstract

objectiveTo determine risk-reducing early salpingectomy and delayed oophorectomy (RRESDO) acceptability and effect of surgical prevention on menopausal sequelae/satisfaction/regret in women at increased ovarian cancer (OC) risk.

designMulticentre, cohort, questionnaire study (IRSCTN:12310993).

settingUnited Kingdom (UK). POPULATION: UK women without OC ≥18 years, at increased OC risk, with/without previous RRSO, ascertained through specialist familial cancer/genetic clinics and BRCA support groups.

methodsParticipants completed a 39-item questionnaire. Baseline characteristics were described using descriptive statistics. Logistic/linear regression models analysed the impact of variables on RRESDO acceptability and health outcomes. MAIN OUTCOMES: RRESDO acceptability, menopausal sequelae, satisfaction/regret.

resultsIn all, 346 of 683 participants underwent risk-reducing salpingo-oophorectomy (RRSO). Of premenopausal women who had not undergone RRSO, 69.1% (181/262) found it acceptable to participate in a research study offering RRESDO. Premenopausal women concerned about sexual dysfunction were more likely to find RRESDO acceptable (odds ratio [OR] = 2.9, 95% CI 1.2-7.7, P = 0.025). Women experiencing sexual dysfunction after premenopausal RRSO were more likely to find RRESDO acceptable in retrospect (OR = 5.3, 95% CI 1.2-27.5, P < 0.031). In all, 88.8% (143/161) premenopausal and 95.2% (80/84) postmenopausal women who underwent RRSO, respectively, were satisfied with their decision, whereas 9.4% (15/160) premenopausal and 1.2% (1/81) postmenopausal women who underwent RRSO regretted their decision. HRT uptake in premenopausal individuals without breast cancer (BC) was 74.1% (80/108). HRT use did not significantly affect satisfaction/regret levels but did reduce symptoms of vaginal dryness (OR = 0.4, 95% CI 0.2-0.9, P = 0.025).

conclusionData show high RRESDO acceptability, particularly in women concerned about sexual dysfunction. Although RRSO satisfaction remains high, regret rates are much higher for premenopausal women than for postmenopausal women. HRT use following premenopausal RRSO does not increase satisfaction but does reduce vaginal dryness. TWEETABLE ABSTRACT: RRESDO has high acceptability among premenopausal women at increased ovarian cancer risk, particularly those concerned about sexual dysfunction.

Indexed as

Attitude to HealthAdolescentAdultAgedAged, 80 and overFemaleGenetic Predisposition to DiseaseHealth Care SurveysHumansLinear ModelsMiddle AgedOvarian NeoplasmsOvariectomySalpingectomyUnited KingdomYoung AdultAcceptabilityBRCAovarian cancerrisk-reducing early salpingectomy with delayed oophorectomy

Identifiers

PMID32803845
PMCPMC7614715
OpenAlexW3043565096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.